Case Report
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jul 26, 2022; 10(21): 7474-7482
Published online Jul 26, 2022. doi: 10.12998/wjcc.v10.i21.7474
Programmed cell death-1 inhibitor combination treatment for recurrent proficient mismatch repair/ miscrosatellite-stable type endometrial cancer: A case report
Chong-Ya Zhai, Lu-Xi Yin, Wei-Dong Han
Chong-Ya Zhai, Department of Medical Oncology, Xiasha Campus, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou 310020, Zhejiang Province, China
Lu-Xi Yin, Wei-Dong Han, Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou 310020, Zhejiang Province, China
Author contributions: Zhai CY participated in clinical treatment and prepared the manuscript; Yin LX sorted out the materials and checked the manuscript; Han WD is the doctor in charge of the case.
Supported by the Hangzhou Health and Family Planning and Science and Technology Program, No. OO20190347.
Informed consent statement: Informed written consent was obtained from the patient for the publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wei-Dong Han, MD, Chief Doctor, Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, No. 3 Qingchun East Road, Hangzhou 310020, Zhejiang Province, China. hanwd@zju.edu.cn
Received: November 27, 2021
Peer-review started: November 27, 2021
First decision: January 12, 2022
Revised: January 22, 2022
Accepted: June 3, 2022
Article in press: June 3, 2022
Published online: July 26, 2022
Processing time: 226 Days and 1.3 Hours
Core Tip

Core Tip: Endometrial cancer (EC) with proficient mismatch repair/miscrosatellite-stable (pMMR/MSS)-type hardly responds to immune checkpoint therapy. This case reported a satisfactory outcome with well-tolerated toxicities using toripalimab combined with anlotinib treatment in an EC patient with pMMR/ MSS-type. Although need further clinical evidence, programmed cell death-1 inhibitor combined anti-angiogenesis therapy may present an option for EC patients with pMMR/MSS-type after multi-line treatment.